Victory Capital Management Inc. Purchases 154,038 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Victory Capital Management Inc. lifted its stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 10.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,680,347 shares of the company's stock after buying an additional 154,038 shares during the period. Victory Capital Management Inc. owned approximately 3.59% of Omnicell worth $58,745,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Principal Financial Group Inc. lifted its holdings in Omnicell by 2.6% during the 1st quarter. Principal Financial Group Inc. now owns 244,644 shares of the company's stock worth $8,553,000 after buying an additional 6,288 shares during the last quarter. Illinois Municipal Retirement Fund lifted its holdings in Omnicell by 10.2% during the 1st quarter. Illinois Municipal Retirement Fund now owns 26,550 shares of the company's stock worth $928,000 after buying an additional 2,456 shares during the last quarter. Diversified Trust Co lifted its holdings in Omnicell by 2.3% during the 1st quarter. Diversified Trust Co now owns 22,660 shares of the company's stock worth $792,000 after buying an additional 513 shares during the last quarter. Accurate Wealth Management LLC lifted its holdings in Omnicell by 27.4% during the 1st quarter. Accurate Wealth Management LLC now owns 36,131 shares of the company's stock worth $1,263,000 after buying an additional 7,762 shares during the last quarter. Finally, Bridge City Capital LLC lifted its holdings in Omnicell by 1.6% during the 1st quarter. Bridge City Capital LLC now owns 40,136 shares of the company's stock worth $1,403,000 after buying an additional 650 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Price Performance

Shares of OMCL stock traded down $1.09 during trading hours on Friday, hitting $26.88. The company had a trading volume of 621,402 shares, compared to its average volume of 563,445. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.75. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of 58.44, a PEG ratio of 7.84 and a beta of 0.76. The firm's fifty day moving average is $29.10 and its 200 day moving average is $34.18. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.23 and a current ratio of 1.38.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.10. The company had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. Omnicell had a return on equity of 4.60% and a net margin of 1.87%. The company's revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.03 EPS. On average, sell-side analysts predict that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the company. Wells Fargo & Company restated an "overweight" rating and issued a $37.00 target price (up from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. Wall Street Zen raised Omnicell from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 12th. Benchmark reduced their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Piper Sandler restated an "overweight" rating on shares of Omnicell in a report on Friday, May 23rd. Finally, Bank of America lifted their price objective on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Omnicell presently has an average rating of "Moderate Buy" and an average price target of $44.83.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.